Skip To Main Content
Bartimee Galvan on Muck Rack

Bartimee Galvan

As seen in: Nature, Science Magazine, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bartimee

Contact Bartimee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

TCF3::HLF orchestrates an enhancer-promoter network with activation of MEF2C to promote immature HSC gene expression in leukemia

|
By Valdemar Priebe, Peter Sheridan Dodds, Mohammad A Saad, Bartimee Galvan, Aneta Drakul, Nicola Margelisch, Júlia Aguadé-Gorgorió, Kaivalya Walavalkar, Yun Huang, Hanna K. A. Mikkola, Beat C. Bornhauser, Raffaella Santoro, Jean-Pierre Bourquin
| Science Magazine Verified
Abstract Oncogenic fusion transcription factors (TFs) frequently drive hematopoietic malignancies by altering gene expression in key developmental programs. TCF3::HLF is a fusion TF that characterizes a rare, treatment-resistant subtype of B cell acute lymphoblastic leukemia [t(17;19) TCF3::HLF-positive B-ALL]. Despite its clinical significance, the mechanisms by which TCF3::HLF induces leukemia are unclear.
Open in Who Shared Issue with article?

TCF3::HLF Orchestrates an Enhancer-Promoter Network with Activation of MEF2C to Promote Immature HSC gene Expression in Leukemia

|
By Júlia Aguadé-Gorgorió, Valdemar Priebe, Aneta Drakul, Bartimee Galvan
| BioRxiv
Abstract Oncogenic fusion transcription factors (TFs) frequently drive hematopoietic 23 malignancies by altering gene expression in key developmental programs. TCF3::HLF is 24 a fusion TF that characterizes a rare, treatment-resistant subtype of B-cell acute 25 lymphoblastic leukemia (t(17;19) TCF3::HLF-positive B-ALL). Despite its clinical 26 significance, the mechanisms by which TCF3::HLF induces leukemia are unclear.
Open in Who Shared Issue with article?
See all 2 articles